Year: 2024
Type: review
Abstract: The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
Source: Pharmaceuticals
DOI: 10.3390/ph17010076
Institutions: German Cancer Research Center, Helmholtz-Zentrum Dresden-Rossendorf, National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden, German Cancer Consortium (DKTK) Dresden, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,296
Funder: National Cancer Institute
OpenAlex ID: W4390673232